Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eculizumab in PNH in China
NCT05886244Phase 3Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jul 2023
- Primary completion
- Apr 2025
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of eculizumab in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Alexion Pharmaceuticals. Started Jul 2023; status: completed.
02
Drugs
eculizumab
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT05886244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05886244.